Company intelligence / Profile preview

Merckle Biotec

Ulm, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

Merckle Biotec was the specialized biotechnology arm of the Merckle Group and Ratiopharm, based in Ulm, Germany. The company was a pioneer in the European biosimilars market, successfully developing and launching one of the first biosimilar versions of filgrastim. In 2010, Teva Pharmaceutical Industries acquired Ratiopharm, including Merckle Biotec, for approximately $5 billion. This acquisition provided Teva with advanced biologics manufacturing capabilities and a robust biosimilar pipeline, which have since been integrated into Teva's global biopharmaceutical operations.

Therapeutic areas: Hematology
Modalities: BiologicRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Merckle Biotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merckle Biotec.

Explore the full profile